📊 Backtest📒 Journal Updated 29/09/2026
← 🔥 Turbo
📐 Simulate Position
STALE?Report written 6 days ago · at $1.03entry levels may be stale — re-check before acting

OCGN

Moonshot
Ocugen, Inc. · NASDAQ · Healthcare / Biotechnology
$1.03
▲ 0.98%
MCap ~$349M
$1.03 at Sep 28, 2026 close (+0.98%), near the bottom of its 52-week band ($0.97-$2.73). Down from $1.23 at the Aug 4 report (-16%) after the OCU400 rolling-BLA timeline slipped in late Aug/early Sep. Stock has stabilized in the $1.00-$1.04 range over the past week.
BusinessGene therapy · Modifier gene therapy platform (OCU400/OCU410/OCU410ST) targeting retinitis pigmentosa, geographic atrophy, and Stargardt disease — deeply discounted small-cap whose near-term regulatory catalyst just slipped, with the real pivotal readout now Q1 2027
Thesis

The primary catalyst this report was built around — OCU400's rolling BLA filing start in Q3 2026 — did NOT fire as planned. The FDA clarified it requires Phase 3 topline data in a pre-BLA meeting before agreeing to a rolling submission schedule, so the de-risking waypoint investors were tracking vanished: there is no meaningful OCU400 regulatory event now until the Phase 3 liMeliGhT topline lands in Q1 2027, with BLA submission still targeted for Q2 2027 (the approval timeline itself hasn't slipped, only the interim milestone did). The stock fell ~16% on this news and hasn't recovered. Thesis WEAKENED, not broken: cash runway is strong (survival check clears — $100.4M cash as of Jun 30, 2026, extended to 2028 via a $130M convertible note raise closed in Q2 2026), OCU410 Phase 3 (ArMaDa3, 237 patients) dosed its first patient Sep 1, 2026, and OCU400 picked up a minor positive — provisional approval + priority designation in The Bahamas (Sep 25, 2026) under an expanded-access framework, though this is a small ex-US proof point, not a US regulatory event. The nearest real catalyst is now OCU410ST interim Stargardt data, still guided for Q3 2026 (i.e., within days of this report) — a non-binary, process-style readout, not the pivotal event. Analyst consensus has come down slightly (avg $9.50 across 5 analysts vs $11.43 previously) with a genuine split: Canaccord cut to $11, HC Wainwright and Oppenheimer raised/initiated at $10, Chardan reiterated $7, Weiss upgraded to Sell — even the reduced consensus still implies triple-digit nominal upside, which this report deliberately discounts per the turbo lane's own optimism-bias data.

📝 Primary Verdict · Core Holding
SPECULATIVEMoonshot

Very small starter position — this report's original catalyst (rolling BLA start) slipped to Q1/Q2 2027, and turbo's own entry-timing data shows -13.7% median drawdown from report price to catalyst (n=19, 79% negative), so Entry 1 is NOT preferred; size small and prefer the Entry 2 dip zone, which already sits near the 52-week low. fda_decision catalystType is a lane leader (+9.3pp median excess vs +2.0pp overall, n=10) — a real tailwind for the imminent OCU410ST interim data, but this is an interim readout, not the pivotal one.

81
score / 100 ⓘ
⚡ Catalyst
🧬 OCU410ST Interim Data (Stargardt Disease)~DAYS (Q3 2026 GUIDANCE)

Interim analysis of the OCU410ST Phase 2/3 pivotal confirmatory trial, guided for Q3 2026 by the company — i.e., within days of this report's date. A process/interim readout, not a single clean binary; topline Phase 2/3 data isn't expected until Q2 2027.

~Sep 30, 2026
🩺 OCU400 Phase 3 liMeliGhT Topline Data~4 MONTHS OUT

The real pivotal OCU400 readout — the previously-expected Q3 2026 rolling BLA start was reframed away because the FDA requires this topline data first. BLA submission still targeted Q2 2027.

Q1 2027
🌴 OCU400 Bahamas Expanded Access (minor, already fired)ALREADY FIRED

Sep 25, 2026: OCU400 received provisional approval and priority designation under The Bahamas' Longevity and Regenerative Therapies Act, targeting first patient treatment within 90 days of full LARTA approval. A small ex-US proof point, not a material financial catalyst.

Sep 25, 2026
🎯 Entry Point
Entry 1
$1.03
Current price, near 52-week lows post the BLA-delay selloff. Turbo's own entry-timing data shows the median position is down -13.7% by the time a name reaches its catalyst (n=19, 79% of windows negative), so this level is not the preferred entryNow (small)
Entry 2PREFERRED
$0.85–0.92
Dip zone matching the turbo lane's -13.7% median entry-to-catalyst drawdown — this range sits at or just below the current 52-week low, meaning a fair amount of pessimism may already be priced in by the time it's reachedIf dips
Entry 3
$0.70
Deep dip below the 52-week low — only if the OCU410ST interim data disappoints or sector risk-off deepensIf sector selloff
✅ Take Profit
TP1
Base — OCU410ST interim data lands roughly in line, market gives a partial, cautious re-rate given the BLA-delay overhang
$1.29
+25%
TP2
Bull — OCU410ST data clearly positive, sentiment recovers meaningfully from the BLA-delay selloff
$1.96
+90%
TP3 🌙
Moon — OCU410ST data beats + early Q1 2027 OCU400 topline anticipation builds + partnership/licensing speculation (MENA-style deal precedent)
$3.61
+250%
🔴 Stop Loss
Tight Stop
Below the dip-zone floor — set wider than the fda_decision catalystType's own -18.4% median MAE (n=10) per the feedback prior
$0.77
-25%
Hard Stop
Well below the 52-week low — market has stopped pricing in any near-term catalyst
$0.57
-45%
Risk / Reward
vs TP2, using the wider MAE-compliant tight stop
3.6 : 1
⚠ Micro-cap biotech — expect violent overnight gaps both ways, especially around the imminent OCU410ST readout
📅 Estimate Date
OCU410ST interim data (Stargardt)
Company-guided for Q3 2026 — imminent as of this report; non-binary interim readout
~Sep 30, 2026
Q3 2026 guidance
OCU400 Phase 3 liMeliGhT topline
The real pivotal readout — FDA requires this before rolling BLA can begin
Q1 2027
Q1 2027 per company guidance
OCU400 BLA submission
Timeline unchanged from prior guidance despite the rolling-start delay
Q2 2027
Q2 2027
📈 Possible Up % — Scenario Spread
Bear
-40%
$0.62
Base
+25%
$1.29
Bull
+90%
$1.96
Moon
+250%
$3.61
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Last confirmed Fed action: held at 3.50-3.75% on Jul 29, 2026 with 3 hawkish dissents favoring a hike — rate-hike tail risk into year-end hasn't gone away
Inflation
Core PCE last confirmed at 3.3% YoY, well above the 2% target
Sector Impact
Small-cap biotech is highly sensitive to risk appetite and rates as a long-duration, cash-burning sector, but OCGN's own catalyst calendar (imminent OCU410ST interim data, Q1 2027 OCU400 topline) dominates the stock's direction far more than macro does
Summary
Macro risk is secondary here — the delayed regulatory timeline and the imminent OCU410ST interim readout, not the Fed, are what move this stock now
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Canaccord Genuity
Buy$11+968%
Oppenheimer
Outperform$10+871%
HC Wainwright
Buy$10+871%
Chardan Capital
Buy$7+580%
Street consensus (5 analysts)
Moderate Buy$9.5+822%
current price $1.03
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

OCGN✅ Good2025-2026
+75%
in 365 days
Positive preliminary gene-therapy readouts (OCU410 geographic atrophy data)
Ocugen's own stock re-rated cumulatively through 2025 on a string of positive preliminary data — this name has shown it reacts strongly to incremental good news pre-approval.
OCGN❌ BadAug/Sep 2026
-16%
in 14 days
OCU400 rolling BLA start reframed away to Q1/Q2 2027
The near-term de-risking waypoint the prior report's thesis relied on vanished when the FDA required Phase 3 topline data first — a process/timeline miss, not a data miss, but the market de-rated the stock meaningfully anyway.
KPTI❌ BadAug 2026
-69%
in 1 day
Phase 3 XPORT-EC-042 endometrial cancer trial miss
A clean primary-endpoint miss triggered a same-day collapse — the sector base rate for a genuine binary readout failure, useful context even though OCU410ST's upcoming data is only interim.
GOSS❌ Bad2026
-77%
in 1 day
Phase 3 seralutinib PAH trial miss
Another Phase 3 primary-endpoint miss with a near-total single-day wipeout — reinforces how binary a genuine pivotal readout is, versus the milder interim event OCGN faces next.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-25% / -35%) only when trading the earnings spot — not for the core holding (use the -25% / -45% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
+15% to +40% into genuine readouts historically; -16% this cycle on the BLA-timeline reframing2-6 weeks before a genuine readout window historically; this cycle instead saw a de-rate on the removal of an expected milestone

OCGN has repeatedly rallied into positive gene-therapy data windows through 2025-2026 as specialist biotech and retail investors position ahead of quarterly updates — but this report period ran the opposite way: the stock fell ~16% on the OCU400 rolling-BLA delay news (late Aug/early Sep 2026) rather than rallying into a catalyst, since the expected near-term milestone was removed rather than delivered.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +90%
range: +30% to +150%· 2025-2026 (OCGN's own history)
Ocugen's own stock re-rated meaningfully through 2025 on a string of positive preliminary gene-therapy readouts (OCU410 geographic-atrophy data around Jan 2026) — this name reacts strongly to incremental good news even pre-approval, though the imminent OCU410ST readout is only interim, not pivotal, so a smaller reaction is more likely than this historical range
❌ Catalyst Missavg -40%
range: -16% to -77%· Aug/Sep 2026 (OCGN) & Aug 2026 (KPTI)
Two real precedents: OCGN's own -16% de-rate on the Aug/Sep 2026 rolling-BLA delay (a process/timeline miss, not a data miss), and the sector base rate for genuine Phase 2/3 primary-endpoint misses — Karyopharm (KPTI) -69% (Aug 2026), Gossamer Bio -77%. The imminent OCU410ST interim readout is closer in character to the milder, process-style miss than a clean binary failure.
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio

Ultra-small-cap, pre-approval biotech whose near-term regulatory catalyst just slipped two quarters — survival check clears (cash to 2028) but real dilution overhang persists from the convertible notes/warrants, and the imminent OCU410ST readout is interim, not pivotal. Size very small.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-25%($0.77)
Below the dip-zone floor ahead of the imminent OCU410ST interim data — set wider than the fda_decision bucket's own -18.4% median MAE per the feedback prior
After Catalyst (Bad Result)-35%
If the OCU410ST interim data disappoints or the OCU400 timeline slips again, exit — don't wait for the Q1 2027 pivotal OCU400 readout to bail you out
📎 Sources

Generated 2026-09-29 · Not financial advice